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Abstract  
BACKGROUND: The rapidly increasing prevalence of childhood obesity became a major burden on health 
worldwide, giving an alarm to clinicians and researchers. Adipocytes act as an active endocrine organ by 
releasing plenty of bioactive mediators (adipokines) that play a major role in regulating metabolic processes. 
Apelin is a recently identified adipokine that is expressed in adipocytes.  
AIM: The current work aimed to uncover the relation between serum apelin and childhood obesity and its related 
complications as hypertension and hyperglycemia 
METHOD: A group of 50 obese and 31 non-obese; sex- and age-matched children were enrolled in our study with 
a mean age of (9.5 ± 2.1) and (8.7 ± 1.3) respectively. Anthropometric measurements, blood pressure, were 
assessed in all studied participants, we also determined the lipid profile, serum insulin, fasting blood glucose 
(FBG) level, HOMA-IR and serum apelin.  
RESULTS: Obese children had higher levels of HbA1c, FBG, serum insulin, HOMA-IR, total cholesterol, 
triglycerides, low-density lipoprotein (LDL) and diastolic blood pressure (DBP Z-score); compared to controls (all P 
< 0.05). Apelin was significantly higher in obese children versus controls and correlated positively with BMI Z-
Score (P = 0.008), DBP Z-Score (P = 0.02), cholesterol, TG (both P = 0.02), serum insulin (P = 0.003), FBG and 
HOMA-IR (both P = 0.001). Linear regression analysis showed that FBG was the most effective factor in 
predicting the level of serum apelin (P = 0.04). 
CONCLUSION: This work supports the hypothesis that apelin may have a crucial role in the pathogenesis of 
health hazards related to obesity in children including insulin resistance, hypertension and a higher risk of 
occurrence of metabolic syndrome. 
 
 
 
 
 
 
 
Introduction 
 
Obesity in childhood is related to a large 
number of metabolic disorders, 
including insulin resistance [1], dyslipidemia. 
[2], hyperglycemia [3], type 2 diabetes mellitus [4], 
and the risk of cardiovascular complications [5].  
Moreover, obese children tend to become 
obese adults [6]. However, studying childhood obesity 
is important to reduce its incidence and the possibility 
of developing obesity-related complications and other 
metabolic diseases. 
Adipose tissue depots are the most important 
target to mediate significant immune cells infiltration 
contributing to systemic inflammation and insulin 
resistance in obese humans [7]. They represent 
powerful acting endocrine organs by releasing a huge 
amount of bioactive adipokines which play an effective 
role in regulating glucose homeostasis and 
inflammatory process [8]. This pattern of secretion 
reflects adipose tissue function and accounts 
essential for detecting the human susceptibility to 
develop cardiovascular and metabolic complications 
of obesity [9]. 
On initiating adipose tissue inflammation, 
adipokine release is markedly produced by a 
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diabetogenic, pro-inflammatory and atherogenic mode 
[10]. 
The recently known adipokine, Apelin which is 
a peptide of a 12-amino acid, encoded by the APLN 
gene and expressed in human adipocytes [11]. Apelin 
synthesis in adipocytes is stimulated by insulin, and its 
serum levels are found to be higher about diabetes 
mellitus, hyperinsulinemia and insulin resistance [12] 
[13].  
Apelin expression helps in regulation of blood 
pressure [14], cardiac contractility [15], fluid balance 
[16] and activation of ACTH release by the pituitary 
[17]. Most of the previously mentioned studies 
demonstrate that contention presents around the 
levels and the associations of apelin in metabolic and 
cardiovascular disorders. Although relations have 
been reported between apelin and atopic dermatitis 
[18] and insulin resistance in adolescents with 
polycystic ovary syndrome [19].  
Till now, there is no acceptance on if apelin 
levels have a direct relation with childhood obesity or 
not. So, this work aimed to study the relations 
between apelin levels and obesity in children and to 
find out the associations between those levels and 
obesity-related complications including hyperlipi-
demia, insulin resistance and hypertension. 
 
 
Patients and Methods 
 
This case-control study included 81children 
classified as 50 obese children compared to 31 
healthy control who were recruited from child health 
Clinic in Medical and Scientific Centre of Excellence, 
National Research Center. 
This includes full personal, history of systemic 
diseases, drug administration (as corticosteroids), and 
symptoms covering various systems, and family 
history of chronic non- communicable diseases 
(obesity, diabetes, cardiovascular diseases and 
hypertension).  
All anthropometric measurements have been 
obtained using standardised equipment and following 
the recommendations of the International Biological 
program [20].  
Assessment of body mass index (BMI) was 
done using categories reported by the World Health 
Organization (WHO) Child Growth Charts Standards 
for age and sex defined as the weight in kilograms 
divided by the square of the height (kg/m
2
) [21]. 
Weight for age, height for age and BMI Z-score were 
determined using the new WHO reference [22]. 
Waist Circumference was measured using 
inelastic insertion tape to the nearest 0.1 cm, with the 
subject in a standing position; the tape was applied 
horizontally midway between the lowest rib margin 
and the iliac crest. Assessment of waist circumference 
was done using categories reported by Fernandez et 
al., 2004 [23]. Thorough medical general examination 
(head & neck, chest, heart, abdomen, upper &lower 
limbs) including measurement of systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) 
then blood pressure Z-score was determined using 
the German references [24]. 
Blood samples were withdrawn from patients 
and controls after overnight fasting (> 12 hours). 
Fasting venous blood samples were collected in 
heparinised centrifuge tubes. Serum was separated 
by centrifugation (3000 rpm, 15 min). Separated 
serum aliquots were removed and stored frozen at -
20
0
C until further analyses were carried out, following 
tests were performed: Fasting serum glucose, fasting 
serum insulin, Cholesterol, Triglycerides (TG), high-
density lipoprotein (HDL)-cholesterol, lowh-density 
lipoprotein (LDL)-cholesterol were measured by 
calorimetric method. While serum apelin levels 
measured by quantitative commercial enzyme-linked 
immunosorbent assay ELISA kit supplied from 
Elabscience Biotechnology Co., Ltd, WuHan, China- 
Catalog No: E-EL-H0456 (www.elabscience.com), 
detection range was between 62.5-400 pg/ml [25]. 
Insulin resistance was estimated by using the 
Homeostasis Model Assessment for insulin resistance 
(HOMA-IR), which was calculated according to the 
known formula, Insulin resistance being defined as a 
HOMA-IR index > 3.16). The greater the HOMA-IR 
value, the greater the level of insulin resistance [26].  
Data management and analysis were 
performed using the Statistical Package for Social 
Sciences (SPSS) v. 21.  
Numerical data were summarised using 
means±standard deviations. Comparisons between 
groups for normally distributed numeric variables were 
made using the Student’s t-test while for non-normally 
distributed numeric variables were done by Mann-
Whitney test. To measure the strength of association 
between numeric variables, Pearson’s correlation 
coefficients were computed. All p-values are two-
sided. Linear regression analysis was performed to 
predict risk factors significantly associated with an 
increased level of Apelin. P value was considered 
statistically significant when it was less than 0.05. 
 
 
Results 
 
Fifty obese and thirty-one non-obese Egyptian 
children were included in this study; all were age-and 
sex-matched. Mean age was 9.5 ± 2.1 and 8.7 ± 1.3 
years in obese children and control groups, 
respectively. 
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Table 1: Anthropometric data of obese children versus 
controls 
variable 
Obese (n = 50) Control (n = 31) 
P-value 
Mean ± SD 
Age 9.5 ± 2.1 8.7 ± 1.3 0.185 
Wt. z-score 2.4 ± 1.1 0.97 ± 0.42 0.000* 
Ht. z-score -0.7 ± 0.98 -0.9 ± 1.2 0.456 
BMI z-score 2.8 ± 0.7 1.6 ± 0.6 0.000* 
(DBP) Z-Score 0.7 ± 0.8 0.2 ± 0.4 0.013* 
(SBP) Z-score 0.4 ± 0.8 0.1 ± 0.7 0.178 
Waist circumference 99.4 ± 17.5 64.7 ± 10.9 0.000* 
Hip circumference 110.5 ± 16.8 86.7 ± 12.2 0.000* 
Waist/hip ratio (WHR) 0.9 ± 0.2 0.8 ± 0.3 0.04* 
Mid arm circumference (MAC) 32.1 ± 6.3 17.3 ± 4.2 0.000* 
*(P ≤ 0.05) is significant. 
 
Table 1 shows that the obese group had 
significantly higher weight Z-score, BMI Z-score, DBP 
Z-score, waist circumference, hip circumference, 
WHR, MAC (all P < 0.05) than the control group. 
Table 2: Biochemical features of the studied groups 
Variable Obese (n = 50) Control (n = 31) P-value 
Mean ± SD 
Apelin 2531 ± 547.8 1107.1 ± 436.7 0.000** 
Cholesterol 196.7 ± 41.9 94.5 ± 11.1 0.000** 
TG 114.6 ± 34.4 83.7 ± 20.6 0.000** 
HDL 45.3 ± 9.5 53.3 ± 8.2 0.000** 
LDL 121.4 ± 37.4 38.8 ± 8.4 0.000** 
Fasting blood Glucose (FBG) 98.8 ± 16.4 73.3 ± 12.9 0.000** 
Insulin 15.1 ± 3.9 9.4 ± 2.3 0.038* 
HOMA-IR 4.7 ± 1.3 1.8 ± 0.9 0.001* 
* Significant difference (P ≤ 0.05); ** Highly significant difference (P ≤ 0.01). 
 
Obese children had significantly higher 
Cholesterol, TG, LDL, FBG, Insulin, HOMA-IR, and 
significantly low HDL compared to the control group. 
Also apelin levels were found to be higher in obesity 
group (Table 2). 
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Figure 1: Correlation between apelin level and diastolic blood 
pressure in obese cases 
 
Correlation analysis of levels of serum apelin 
with anthropometric parameters and biochemical 
findings showed significant positive correlations 
between apelin and weight z score, BMI z score, 
waist, SBP, DBP z score (Figure 1), cholesterol, TG, 
Glucose, insulin and HOMA-IR (Figure 2) in the obese 
group.  
No correlations were found between apelin 
levels and age, height, skinfold thickness, WHR, 
MAC, HDL, LDL. 
 
 
Figure 2: Correlation between apelin level and HOMA-IR in obese 
cases 
 
 
Discussion 
 
Obesity is considered a widely spread chronic 
illness and a major risk factor for the development of 
metabolic syndrome, type 2 diabetes mellitus and 
cardiovascular diseases [27]. Many studies have 
agreed that visceral obesity is strongly related to 
hypertension, dyslipidemia, hyperglycemia, and IR 
[28]. Severe adiposity may be the cause of some 
metabolic diseases such as type 2 diabetes (T2D), 
hypertension, insulin resistance, polycystic ovarian 
diseases and some types of cancer [29]. 
Table 3: Predictive factors for an increased level of Apelin in 
obese children as estimated by linear regression 
Variable Apelin 
 B Sig. 
BMI Z-score 0.176 0.605 
SBP Z-score 0.266 0.132 
DBP Z-Score 0.037 0.842 
Cholesterol 0.160 0.344 
TG 0.117 0.402 
FBG 0.455 0.038* 
Insulin 0.488 0.371 
HOMA-IR -0.622 0.308 
*P < 0.05, the relationship is statistically significant; Factors entered: BMI.SBP Z-score, 
DBP Z-score, TG, Cholesterol, glucose, Insulin, HOMA-IR; Dependent variable: Apelin; 
Linear regression analysis showed that FBG was the main predictor serum apelin levels (P 
= 0.038). 
 
Adipose tissue hormones called adipokines 
such as adiponectin, leptin, and apelin have a major 
role in obesity-related comorbidities and complications 
[12] [30]. High plasma levels of apelin have been 
detected by many authors in severe obesity and 
related to adiposity [31] [32]. 
The current work investigated the data of 
obese and non-obese groups of Egyptian children to 
find out correlations if present between apelin and 
obesity-related hazards, especially insulin resistance, 
hyperlipidemia, hypertension, and insulin sensitivity.  
Serum insulin, TG, TC, LDL, and HOMA-IR 
were found to be significantly higher in all obese 
subjects when compared to controls in our study, 
these results were in agreement with Ba et al., 2014 
 El Wakeel et al. Serum Apelin and Obesity-Related Complications in Egyptian Children 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Aug 20; 6(8):1354-1358.                                                                                                                                                  1357 
 
[33], also we observed a significantly higher Apelin 
level in obese cases when compared to non-obese 
and this agreed with Boucher et al., 2005 [12] who 
found similar results and supposed that adipose tissue 
is a major source of apelin release, and that 
expression of apelin and apelin receptors (APJ) both 
increase in fat cells of obese subjects.  
In the current study, we found that serum 
apelin levels were positively correlated with BMI. This 
came in agreement with a study done by Sheibani et 
al., 2012 supposing an important role of apelin in the 
pathogenesis of obesity and obesity-related 
complications [34]. Also, many studies revealed that 
apelin levels were higher in obese individuals in 
comparison to none-obese and correlated positively 
with BMI [31] [32]. In contrast, Reinehr et al., 2011 
found that changes in apelin levels were not linked to 
weight reduction in obese children in a study 
assessed risk factors before and after one year of 
regular lifestyle modulations [35].  
Moreover, in our study we found that there 
was a significantly positive correlation between Apelin 
and insulin, similar finding had been detected by other 
authors and explained by that the increased levels of 
both serum apelin and insulin could reflect impairment 
apelin homeostasis and also supposed that higher 
serum insulin concentrations could increase serum 
apelin levels [12]. 
In the current work, there was a significant 
increase in HOMA-IR in obese children in comparison 
to control group, also we found a significant positive 
correlation between Apelin and HOMA-IR and this in 
concordance with Li et al., 2006 who described a 
positive correlation with HOMA-IR in patients with type 
2 diabetes and impaired glucose tolerance [36].  
There is a potent correlation between obesity 
and parameters of insulin sensitivity caused by apelin 
released by adipose tissue [12]. It was mentioned that 
apelin suppresses the secretion of insulin plasma 
systems [37] [38]. Many authors also suggested that 
apelin may act as powerful insulin sensitising factor 
and could be a potent target for diabetes elimination 
and management due to its ability to increase insulin 
sensitivity [11]. 
In the present study, we observed a 
significant difference in diastolic blood pressure 
between obese and control groups, and there was a 
significant positive correlation between Apelin and 
SBP, DBP. These findings don’t agree with Samir et 
al., 2015, who found a similar increase in serum 
apelin in obese hypertensive and nonhypertensive 
obese individuals but they found no correlation 
between systolic blood pressure, diastolic blood 
pressure, and serum apelin [38]. Also, Rittig et al., 
2011, who evaluated the relation between apelin 
serum levels, body fat distribution and insulin 
sensitivity/resistance as dependent cardiovascular risk 
factors; blood pressure was reported to be unaffected 
by serum apelin levels [39].  
In conclusion, apelin levels are significantly 
higher in obese children when compared to control 
group and correlate significantly with insulin, HOMA-
IR, lipid profile and hypertension in these children 
suggesting that this adipokine may act as potential 
biomarkers for evaluation of metabolic risk factors in 
obesity. 
Further studies with large sample size are in 
need to explain the role and mechanisms of action of 
apelin in association with obesity-related markers and 
metabolic diseases  
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